High Throughput Genomics (HTG) Announces Genomic Screening Technology Agreement with Celgene Corporation
Tucson, AZ August 19, 2002- High Throughput Genomics, Inc. ("HTG") announced today that it has entered into an agreement with Celgene Corporation to supply Celgene's target and Drug Discovery platform with HTG's Omix Imager™ and ArrayPlate™ Kits. Under the terms of the agreement, HTG will install at Celgene an Omix Imager system for high throughput genomic screening and will develop and supply ArrayPlate Kits containing sets of genes associated with disease pathways targeted by Celgene's drug discovery programs. HTG also will develop and supply to Celgene genomic profiling kits for use in chemicogenomics and pharmacogenomics studies. The ArrayPlate Kits and the Omix Imager will be incorporated into Celgene's target and drug discovery process and used to detect changes in disease- and drug-associated gene Expression profiles.
HTG's ArrayPlate consists of a standard 96-well microplate where each individual well can be programmed for the multiplexed measurement of any set of up to approximately 100 different DNA, RNA or protein target molecules using custom reagent sets (in the case of RNA and DNA, GeneSets™). The RNA expression and DNA assays rely on an optimized and simplified, automation-friendly multiplexed nuclease protection assay (m-NPA™) that requires only the lysis of samples, with no extraction, purification or amplification needed.
Dr. Alan Lewis, President of the Signal Research Division of Celgene Corporation, commented: "The technology we are using from HTG will further enhance our proven, state-of-the-art drug discovery capabilities and allow us to implement pharmacogenomics studies to better understand pathogenesis and management of disease and ultimately to develop personalized medicine strategies." Dr. Bruce Seligmann, Chief Executive Officer of High Throughput Genomics said: "Celgene is a leading drug discovery and development company, and we are excited that they have chosen the ArrayPlate to screen their compounds. They had a choice of partners and we are delighted that they have elected to work with HTG."
HTG markets ArrayPlate assays to pharmaceutical researchers who use the product for target validation, compound screening, safety, and metabolism optimization in drug discovery or diagnostics. Clients can use the ArrayPlate technology on a service basis or through purchase of custom kits, software, and imagers, to establish and validate custom assays, test samples, or perform high throughput screening. and optimization using HTG's proprietary combinatorial chemistry and libraries.
Weitere News aus dem Ressort Forschung & Entwicklung
Diese Produkte könnten Sie interessieren
Limsophy LIMS von AAC Infotray
Optimieren Sie Ihre Laborprozesse mit Limsophy LIMS
Nahtlose Integration und Prozessoptimierung in der Labordatenverwaltung
GUS-OS Suite von GUS
Ganzheitliche ERP-Lösung für Unternehmen der Prozessindustrie
Integrieren Sie alle Abteilungen für nahtlose Zusammenarbeit
Holen Sie sich die Life-Science-Branche in Ihren Posteingang
Ab sofort nichts mehr verpassen: Unser Newsletter für Biotechnologie, Pharma und Life Sciences bringt Sie jeden Dienstag und Donnerstag auf den neuesten Stand. Aktuelle Branchen-News, Produkt-Highlights und Innovationen - kompakt und verständlich in Ihrem Posteingang. Von uns recherchiert, damit Sie es nicht tun müssen.
